Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
Final analysis from IGNITE Phase 2 clinical trial planned for second quarter of 2025: The Company plans to report the final analysis from the IGNITE Phase 2 clinical trial, including all patients at 12 months dosed with either 20 mg/kg or 40 mg/kg of iluzanebart in the second quarter of 2025.
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
Fourth Quarter 2024 Highlights On Dec. 20, 2024, Quoin announced the successful completion of a $6.8 million public offering, bolstering the company’s financial position to support ongoing clinical development and corporate initiatives. The offering included significant participation by Quoin’s entire executive team.
ToplineThis will be Tesla’s weakest quarter for car deliveries since 2022, according to JPMorgan analysts, as the polarizing, ...
Clear Secure's Q4 2024 earnings showed impressive growth, with revenues up 20.7%, free cash flow up 48%. See why I upgrade ...
U.S. independent power producer Vistra Corp reported fourth-quarter profit on Thursday, as strong electricity demand from AI data centers helped boost the company's earnings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback